Atrial fibrillation: diagnosis and management
KEYWORDS: atrial, fibrillation, atrial fibrillation, committee, people, risk, evidence, recommendations, ablation, anticoagulation, stroke, treatment, bleeding, control, practice

follow the guidance in the British National Formulary and the MHRA advice on direct- acting oral anticoagulants, in particular for advice on dosages in people with renal impairment, reversal agents and monitoring. [2021] 1.6.3 Offer anticoagulation with a direct-acting oral anticoagulant to people with atrial fibrillation and a CHA DS -VASc score of 2 or above, taking into account the risk 2 2 of bleeding. Apixaban, dabigatran, edoxaban and rivaroxaban are recommended as options, when used in line with the criteria specified in the relevant NICE technology appraisal guidance (see the section on direct-acting oral anticoagulant treatment options). [2021] 1.6.4 Consider anticoagulation with a direct-acting oral anticoagulant for men with atrial fibrillation and a CHA DS -VASc score of 1, taking into account the risk of 2 2 bleeding. Apixaban, dabigatran, edoxaban and rivaroxaban are recommended as options, when used in line with the criteria specified in the relevant NICE technology appraisal guidance (see the section on direct-acting oral anticoagulant treatment options). [2021] 1.6.5 If direct-acting oral anticoagulants are contraindicated, not tolerated or not suitable in people with atrial fibrillation, offer a vitamin K antagonist. See the section on self-monitoring and self-management of vitamin K antagonists. [2021] 1.6.6 For adults
